EMBRACA was a randomized, open-label, phase III study in which patients with HER2-negative, gBRCA-mutated advanced BC were randomized in a 2:1 ratio to talazoparib (1 mg daily) or physician’s choice of standard monotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine, 21 days/cycle) [69]. Here, ERBB2 is linked to breast cancer.